Bone loss (osteopenia, osteoporosis) results from an imbalance between osteoblast bone formation and osteoclast bone resorption, accelerated by GH/IGF-1 decline, inflammation, and hormonal changes. Peptide research targets bone remodeling by enhancing osteoblast activity, stimulating GH/IGF-1 pathways, and reducing inflammatory bone destruction.
1. Ipamorelin + CJC-1295 — GH-Mediated Bone Formation
GH and IGF-1 are the primary drivers of osteoblast activity and bone mineral density. Ipamorelin/CJC restores youthful GH pulsatility, which translates directly into enhanced bone formation markers, increased collagen synthesis in bone matrix, and improved calcium utilization.
Dosing Protocol: 200–300 mcg Ipamorelin + 100–200 mcg CJC-1295 SubQ nightly. 5 on/2 off. Long cycles of 16–24 weeks for bone remodeling endpoints.
2. BPC-157 — Bone Healing / Angiogenesis
BPC-157 accelerates bone healing through angiogenesis promotion (critical for bone repair) and upregulation of growth factor signaling in bone tissue. It has demonstrated significant acceleration of bone fracture healing in multiple animal models and supports the vascular supply needed for osteoblast function.
Dosing Protocol: 250–500 mcg SubQ daily near bone remodeling sites. Oral BPC-157 (500 mcg) provides systemic support. Cycle: 8–12 weeks.
3. TB-500 — Periosteal Repair / Anti-Inflammatory
TB-500 reduces the inflammatory cytokines (IL-1β, TNF-α) that activate osteoclasts and drive bone resorption. It supports repair of the periosteum (bone covering) and the connective tissue matrix surrounding bone, improving structural integrity beyond just mineral density.
Dosing Protocol: 2 mg SubQ twice weekly for 4–6 weeks, then 2 mg weekly for maintenance. Stack with BPC-157.
4. IGF-1 LR3 — Direct Osteoblast Stimulation
IGF-1 is the most potent direct stimulator of osteoblast proliferation and bone matrix synthesis. IGF-1 LR3 provides sustained IGF-1 activity at bone remodeling sites, promoting new bone formation and opposing the osteoclast-driven resorption that characterizes age-related bone loss.
Dosing Protocol: 20–40 mcg SubQ daily. Cycle: 4 weeks on, 4–6 weeks off. Monitor blood glucose carefully.
Ipamorelin/CJC restores the GH/IGF-1 axis driving bone formation while IGF-1 LR3 provides direct osteoblast stimulation. BPC-157 ensures adequate vascular supply for bone repair and IGF-1 signaling. TB-500 suppresses the inflammatory bone resorption that counteracts new bone formation efforts.
- Langlois JA et al. (2002). IGF-1 and bone density. J Bone Miner Res. DOI: 10.1359/jbmr.2002.17.9.1595
- Seiwerth S et al. (2018). BPC-157 and bone healing. Peptides. DOI: 10.1016/j.peptides.2018.10.008
- Goldstein AL et al. (2010). Thymosin beta-4 in tissue repair. Peptides. DOI: 10.1016/j.peptides.2010.05.006
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).